Weakness in Merrimack Pharmaceuticals (NASDAQ: MACK) following FDA approval of ONIVYDE presents a buying opportunity, according to Eric Criscuolo of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE